February 26, 2018 / 10:21 PM / 6 months ago

BRIEF-DBV Technologies Announces Results From Phase II Study Of Viaskin Milk In Milk-Allergic Patients

Feb 26 (Reuters) - Dbv Technologies Sa:

* DBV TECHNOLOGIES ANNOUNCES RESULTS FROM PHASE II STUDY OF VIASKIN MILK IN MILK-ALLERGIC PATIENTS

* DBV TECHNOLOGIES- IN TRIAL, STATISTICALLY SIGNIFICANT DESENSITIZATION TO MILK OBSERVED IN CHILDREN AGES 2 TO 11 TREATED WITH VIASKIN MILK 300 ΜG FOR 12 MONTHS

* DBV TECHNOLOGIES - IN TRIAL, FOLLOWING ANALYSES OF DATA, 300 ΜG DOSE WAS IDENTIFIED AS MOST EFFECTIVE TESTED DOSE FOR CHILDREN

* DBV TECHNOLOGIES SA - COMPANY EVALUATING OPTIMAL DOSING/PATIENT POPULATION FOR FUTURE STUDIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below